Monograph
C09CA01 - Losartan |
Propably not porphyrinogenic |
PNP |
Rationale
Losartan is a substrate to CYP3A4, CYP2C9 and CYP2C10. No data is pointing to CYP induction or mechanism based inhibition, and losartan is therefore not suspected to be porphyrinogenic. This is also supported by 33 clinical observations of uneventful use of losartan.
Chemical description
Losartan is an angiotensin II receptor antagonist.
Therapeutic characteristics
Antihypertensive
Metabolism and pharmacokinetics
Losartan is a prodrug which is converted into its main active metabolite E3174, a carboxylic acid, by CYP3A4, CYP2C9 (Zaidenstein et al. 2001) and CYP2C10 (Sica et al. 2005). In vitro studies indicate that CYP2C9 is the major contributor while CYP3A4 oxidation is only significant at very high concentrations of losartan (Yasar et al. 2001). E3174 is 40 times more potent than losartan (Up to date 2013).
Losartan inhibits CYP1A2 (weak), CYP2C19 (weak), CYP2C8 (moderate), CYP2C9 (moderate) and CYP3A4 (weak) (Up to date 2013). In vitro studies state that losartan have modest affinity to CYP2C9 (Taavitsainen et al. 2000). No data is indicating that losartan is a mechanism based inhibitor.
Extensive first pass effect. Half-life elimination: Losartan: 1.5-2 hours; E-3174: 6-9 hours.
Personal communication
Thunell, patient report (n = 1): tolerated. Anderson, patient report (n = 2): tolerated.
IPNet drug reports
Uneventful use reported in 30 patients with acute porphyria.
References
| # |
Citation details |
PMID |
|---|
| * | Scientific articles |
| 1. |
A., Gehr T. W. B., Ghosh S. Clincial Pharmacokinetics of Losartan. Clinical Pharmacokinetics 2005;44(8):797-814.
Sica D. |
|
| 2. |
, Kiukaanniemi K., Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonist. European Journal of Clinical Pharmacology 2000;56:135-140.
Taavitsainen P. |
10877007 |
| 3. |
, Tybring M., Hidestrand M., Oscarson M., Ingelman-Sundberg., Dahl M., Eliasson E. Role of CYP2C9 Polymorphism in Losartan Oxidation. Drug metabolism and disposition 2001;29(7):1051-1056.
Yasar Ü. |
11408373 |
| 4. |
, Soback, S., Gips, M., Avni, B., Dishi, V., Weissgarten, Y., Golik, A., Scapa, E. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Therapeutic Drug Monitoring 2001;23(4):369-373.
Zaidenstein R. |
11477318 |
| * | Drug reference publications |
| 5. |
Up to date. Losartan.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
